Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil.

[1]  G. Huhn,et al.  Nephrotoxicity Associated with Concomitant Use of Ledipasvir‐Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection , 2016, Pharmacotherapy.

[2]  D. Wong,et al.  Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients. , 2016, Journal of hepatology.

[3]  L. Domínguez-Domínguez,et al.  Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy. , 2016, Journal of hepatology.

[4]  David Rey,et al.  Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients , 2015, PloS one.

[5]  R. Chung,et al.  Hepatitis C treatment: an incipient therapeutic revolution. , 2014, Trends in molecular medicine.

[6]  T. Koch,et al.  Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs. , 2013, Biochemical pharmacology.

[7]  M. Otto,et al.  Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.

[8]  K. Jhaveri,et al.  Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury , 2016, The American Journal of Gastroenterology.

[9]  M. Aldersley,et al.  Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. , 2016, Journal of hepatology.